

Claims

1. Use of γ -GT inhibitors for the preparation of a pharmaceutical composition for the treatment of a degenerative disease.
2. The use of claim 1, wherein said degenerative disease is a chronic renal disease or an inner ear degenerative condition or injury.
3. The use of claim 2 wherein said chronic renal disease is ROS induced.
4. The use of claim 3, wherein said chronic renal disease is selected from the group consisting of focal glomerulosclerosis, segmental glomerulosclerosis, minimal change nephrosis, inflammatory glomerulopathies, diabetic nephropathy and autoimmuno glomerulopathies.
5. The use of claim 2, wherein said inner ear injury is ROS induced.
6. The use of claim 5, wherein said ROS induced inner ear injury is sensineurial deafness induced by age, physiological status, metabolic status or drugs.
7. The use of claim 6, wherein said drugs are selected from aminoglycosides or cisplatin derivatives.
8. The use of claim 2, wherein said inner ear degenerative condition is otosclerosis.
9. The use of any one of claims 1 to 8, wherein said γ -GT inhibitor is selected from the group consisting of AT-125, Acivicin or its derivatives, γ -glutamyl amino acids and peptides of the general formula γ -Glu-XY, peptides of the general formula (CysGlyX), peptidomimetic glutathion analogues, compounds or derivatives of the type L-2-amino-4-boronobutanoic acid (ABBA), and anilides, such as γ -glutamyl-7-amido-4-methylcoumarin (γ -Glu-AMC).

10. The use of claim 9, wherein X and Y stand for any naturally occurring aminoacid, a modified aminoacid, a oligopeptide or a polypeptide.